B+
Bull case
0%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
CRSP
CRISPR TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Casgevy adoption is accelerating, pediatric expansion broadens the eligible population, and upcoming CTX310, CTX340, CTX460, and zugo-cel data create several potential re-rating points. Secondary coverage reported Q2 EPS of negative $0.94 versus a negative $1.10 consensus estimate and revenue of $10.2 million versus $7 million consensus.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.9.
What can break
Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
Momentum
51
Value
41
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $59.00 · Bull $82.00 · Bear $38.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $84.72
Why
Momentum51 · Δ7d -22.9
Value41 · Δ7d -0.0
Sentiment82 · Δ7d +7.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +7.9.
Contradictions & invalidation
- • Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
- • Clinical, safety, regulatory, and enrollment risk across CTX310, CTX340, CTX460, and zugo-cel.
- • Casgevy commercialization remains dependent on Vertex-led execution, treatment capacity, reimbursement, and broader access.
Catalyst clock
2026-08-03
Q2 results and Casgevy expansion
Lead driver: Sentiment · See AI snapshot
Momentum
51
9% active weight
Current posture
7d trendSoftening
Δ7d
-22.9
Δ21d
-27.1
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
82
62% active weight
Current posture
7d trendImproving
Δ7d
+7.9
Δ21d
+13.7
Why this grade
Composite grade B. Momentum 51.1 / Value 41.2 / Sentiment 82.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$5.25B
Beta
1.72
Shares Out
96.69M
P/E (TTM) · Derived
-8.4
P/S (TTM)
137.09
P/FCF (TTM) · Derived
-13.86
Rev YoY
+1041.4%
EPS YoY
-60.6%
Gross Margin
-1510.7%
Op Margin
-3971.5%
Net Debt
-$1.78B
Current Ratio
17.85
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data